Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Olympus, EndoRobotics partner on global distribution of robot-assisted endoscopic technologies
Distribution agreement, robotics, endoscopy, commercialization - Read more

Madrigal Pharmaceuticals, Arrowhead Pharmaceuticals license ARO-PNPLA3 for MASH, $25M upfront, up to $1B total
Licensing deal, MASH/liver disease, siRNA/RNAi, milestone payments - Read more

Cytokinetics' Myqorzo meets dual Ph3 endpoints in non-obstructive hypertrophic cardiomyopathy trial
Small molecule, cardiovascular, cardiac myosin inhibitor, hypertrophic cardiomyopathy, non-obstructive HCM - Read more

Viridian Therapeutics' (elegrobart) IGF-1R blocker succeeds in Ph3 trial for chronic thyroid eye disease
Antibody, autoimmune, monoclonal antibody, thyroid eye disease, IGF-1R, subcutaneous injection - Read more

Palisade Bio's PALI-2108 (pali-2108) Ph1 data show colon-targeted PDE4 inhibition in ulcerative colitis
Small molecule, autoimmune, PDE4 inhibitor, ulcerative colitis, inflammatory bowel disease - Read more

QurAlis' QRL-201 (stathmin-2 ASO) shows 50% disease progression reduction in Ph2 amyotrophic lateral sclerosis trial
Antisense oligonucleotide, neurological, ALS, STMN2 target, genetic medicine - Read more

Johnson & Johnson's JNJ-4804 (golimumab/guselkumab) advances to Ph3 for ulcerative colitis and Crohn's disease after Ph2 DUET data
Antibody, autoimmune, monoclonal antibody, combination therapy, inflammatory bowel disease, TNF/IL-23 inhibitor - Read more

Hepta's cfDNA methylation assay predicts GLP-1 (semaglutide) response before treatment in metabolic dysfunction-associated steatotic liver disease
Small molecule, metabolic, GLP-1 agonist, MASH, liquid biopsy, precision medicine - Read more

Avalo Therapeutics' (abdakibart) meets primary endpoint in Ph2 trial for moderate to severe hidradenitis suppurativa
Antibody, autoimmune, monoclonal antibody, hidradenitis suppurativa, IL-1β inhibition - Read more

Science 2 Sales builds and runs the entire outbound engine (across email, LinkedIn, and cold calling) for companies selling into biotech & pharma - so your sales team stops researching and starts closing qualified meetings with the decision-makers who can actually sign.

When it comes to outbound lead gen - you get the meetings. We handle everything else.

Learn more and book a free strategy call on our website.

Axsome Therapeutics raises Auvelity peak sales projection to $8B after FDA Alzheimer's agitation approval
Small molecule, neurological, revenue impact, competitive - Read more

Vertex Pharmaceuticals' steady Q1 precedes potential 'iconic' renal portfolio evolution led by povetacicept
Fusion protein, renal disease, rare disease, financial - Read more

Pfizer beats Q1 earnings with $14.5B revenue, maintains 2026 guidance despite COVID portfolio decline
Small molecule, oncology, cardiovascular, financial - Read more

Cytospire raises $83M to develop gamma delta T cell engagers for solid tumors
Oncology, antibody, T cell engager, solid tumors, preclinical - Read more

Dandelion Health raises $14M Series A to advance multimodal clinical AI platform for pharma
AI/ML platform, data analytics, biomarker discovery, clinical trial platform, real-world evidence - Read more

Sanofi invests $294M to expand Toronto AI center, targeting drug discovery and manufacturing acceleration
AI/machine learning, drug discovery, strategic, operational - Read more

Swiss private biotech funding surges 38% to record $1.5B in 2025, marking third straight year of growth
Autoimmune, oncology, rare disease, clinical-stage, small molecule, antibody - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Gilead trims 108 jobs at Arcellx's Redwood City site following $7.8B acquisition close
CAR-T, oncology, major transaction, operational - Read more

Novartis to close German manufacturing site in Wehr by 2028, eliminating 220 jobs
Radioligand therapy, oncology, operational, cost reduction - Read more

BioNTech closes four manufacturing plants, cutting 1,860 jobs to save €500M ($585M) annually by 2029
mRNA vaccine, oncology, cost reduction, operational - Read more

Amarox recalls sertraline batch after citalopram blister strip found mixed in UK packaging
Small molecule, neurological, operational, safety recall - Read more

Pfizer drops (maplirpacept) from pipeline, ending CD47 blocker program for blood cancers after Ph1/Ph2 studies
Antibody, cancer, CD47 inhibitor, blood cancer, B-cell lymphoma - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here